News

20

May, 2022

Youth engagement and participation in clinical trials

Tags: ,

In late April 2022, Mercy Shibemba, one of our PPI experts, sat down with two members of our Youth Trials Board (YTB) to talk about the work that they do and what it’s like to participate in clinical trials as young people living with HIV. What do you do as part of the Youth Trials Board? YTB member 1: I’ve been part of lots of global zoom meetings throughout covid. YTB member 2: A few weeks ago, me and a couple other young people went to do some training with [...]
READ MORE

19

May, 2022

Penta at the Global Child Health Mini-Symposium in Oxford April 7th 2022

 

Penta was highly represented at the Mini-Symposium hosted by Green Templeton College – University of Oxford on the 7th of April 2022 entitled “Serving the children of the world: examining the current research needs in Paediatrics”. The key idea of the symposium was exploring the needs of child health globally and acknowledging the importance of facilitating research collaboration in global health. The topics of the symposium spanned from Perinatal Medicine to Adolescent Health. World class speakers from all over the world as well as students from Oxford, contributed towards making […]

READ MORE

18

May, 2022

Penta investigates cases of acute hepatitis of unknown origin in children

Tags:

On 12 May, a Rapid Communication on the reported increase of acute hepatitis of unknown origin in children was published in Eurosurveillance. The paper outlines the extent and geographical distribution of these unexplained paediatric hepatitis cases in Europe and beyond. It also highlights the challenges of drawing comparisons against a baseline of a syndrome which is not under systematic surveillance and has no standard case definitions in place. Acute hepatitis of unknown origin is a rare paediatric syndrome, which causes severe inflammation of the liver and may require transplantation. Lately, […]

READ MORE

18

May, 2022

RBDCOV initiates the first Phase III clinical trial of HIPRA’s Covid-19 vaccine in immunocompromised people

 

One of the objective of RBDCOV is to test whether the vaccine can reactivate or re-generate a protective immune response against the virus The RBDCOV project, in which Penta is a partner, started a Phase III clinical trial of the Covid-19 vaccine in immunocompromised people, after the Spanish Agency for Medicines and Health Products (AEMPS) authorised it on 9 May. This clinical trial will determine whether an additional dose of HIPRA’s Covid-19 vaccine can generate an immune response in people living with immune system disorders, such as immunodeficiencies or who […]

READ MORE

16

May, 2022

Capacitating the future of research in paediatric HIV

Tags: ,

By design, capacity building is a fundamental part of the UNIVERSAL project. The aim of the project's capacity building activities are to improve the ability of African and European young investigators in designing and conducting clinical trials. As such, the project conducted a Training Needs Assessment (TNA) from March 17th to June 21st 2021 among 108 African early career researchers from Cameroon, Mali, Senegal, Uganda and Zimbabwe who are involved in the project (see fig 1 below). A TNA is the process of collecting and analysing data to determine what [...]
READ MORE

11

May, 2022

The EPIICAL story

 

In 2016 the Early-treated Perinatally HIV-infected individuals: Improving Children’s Actual Life (EPIICAL) consortium began gathering scientists and clinicians specialising in paediatric HIV to work towards establishing new, scientific efforts on the early treatment of HIV to improve the lives of children and ultimately lead to the remission of HIV in children. The main focus of the consortium was the development of a predictive platform to inform treatment strategies that would lead to HIV remission. EPIICAL 2016-2020 succeeded in designing and conducting studies on paediatric HIV which led to the development […]

READ MORE

27

Apr, 2022

The D3 study has screened the first 2 children

 

Great day for the D3 study, today. The first 2 children have been screened for the study at the Prapokklao Hospital in Thailand. Thanks to the MRC CTU and the PHPT team to coordinate this effort. Through D3, we aim to assess whether the combination of DTG/3TC is just as effective as the standard of care in terms of virological suppression in children and adolescents. The trial will also compare the toxicity, adherence, tolerability, acceptability and quality of life in participants of this combination versus that of the standard of […]

READ MORE

26

Apr, 2022

GARDP study reveals that babies are increasingly dying of neonatal sepsis caused by drug-resistant bacterial infections

Tags: ,

Geneva, 26 April 2022 – A large study focusing on newborn babies with clinically diagnosed sepsis has revealed the impact of antibiotic resistance on neonatal sepsis, a major cause of death in newborns. At the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), the Global Antibiotic Research and Development Partnership (GARDP) has released a second wave of findings from its study on the outcomes of more than 3,200 newborns with neonatal sepsis, a life-threatening bloodstream infection that affects up to 3 million babies a year. The study shows that […]

READ MORE

25

Apr, 2022

PentaTr@ining 2022: online course kicks off!

Tags:

Our interactive course PentaTr@ining 2022: ‘HIV & other Congenital Infections’ kicks off today! The innovative online programme comprises 6 interactive and in-depth training modules, a wide variety of real-life clinical cases for discussion, live ‘Q&A’ webinars and dedicated tutoring from our expert international teaching faculty. To consolidate the online training, the course will conclude with a face-to-face workshop at the historic venue of Pontificia Università Urbaniana in Rome, Italy on 28-30 September. The residential course promises an exciting 3-day programme of topical presentations, small group case discussions, and fun quizzes! The key training objective […]

READ MORE

23

Mar, 2022

Borrowing information across patient subgroups in clinical trials

Tags:

An article by investigators within the ODYSSEY trial has been published as Open Access into BMC Medical Research Methodology. The investigators aimed to evaluate a treatment effect in a pre-defined subgroup of interest while borrowing information from a separate patient subgroup, using a Bayesian analysis. A Bayesian analysis enables evidence from data to be combined with prior information from an external sample. Phase III clinical trials demonstrate whether or not medical intervention is effective and safe in a specific population. For various reasons, investigators may choose to evaluate effectiveness and safety […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities